Fcpm Iii Services B.V. Has $48.09 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

Fcpm Iii Services B.V. reduced its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 18.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,970,668 shares of the company’s stock after selling 895,781 shares during the quarter. Replimune Group accounts for approximately 8.2% of Fcpm Iii Services B.V.’s holdings, making the stock its 5th biggest position. Fcpm Iii Services B.V. owned 5.80% of Replimune Group worth $48,085,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Boxer Capital Management LLC acquired a new stake in Replimune Group during the fourth quarter worth $21,754,000. Price T Rowe Associates Inc. MD boosted its holdings in Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Replimune Group in the 4th quarter worth approximately $10,853,000. Wellington Management Group LLP boosted its stake in Replimune Group by 352.5% in the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company’s stock valued at $13,282,000 after buying an additional 854,346 shares in the last quarter. Finally, Artisan Partners Limited Partnership bought a new stake in Replimune Group in the fourth quarter valued at $7,399,000. 92.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on REPL shares. BMO Capital Markets boosted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Performance

REPL stock opened at $7.80 on Friday. The company has a 50 day moving average price of $9.45 and a 200 day moving average price of $11.52. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The stock has a market capitalization of $600.33 million, a PE ratio of -2.54 and a beta of 0.68.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.